In addition to back pain, lower limb movement disorders and even fractures, breast cancer patients have to face the pain caused by the loss of bone mass in their bodies while fighting against the tumor. Endocrine therapy for breast cancer, especially the emergence of aromatase inhibitors, has caused many women to develop osteoporosis prematurely, and what is even more frightening is that this danger often occurs quietly, and once it happens, it causes endless troubles to patients. As we all know, the reason why endocrine therapy can occupy a very high position in breast cancer treatment is that breast cancer is an estrogen-dependent tumor. Endocrine therapy is to inhibit the growth of tumor cells by suppressing the level of estrogen. But unfortunately, the presence of estrogen is almost essential for the female skeleton. One study showed that postmenopausal breast cancer patients who used aromatase inhibitors had 1.5 times the risk of fracture than those who did not. However, the role of aromatase inhibitors should not be dismissed for this reason. On the contrary, it is precisely because of the use of this treatment that the survival of breast cancer patients is significantly prolonged and that the chronic disease of osteoporosis has the opportunity to manifest itself. To give up endocrine therapy in order to reduce the risk of osteoporosis is definitely an act of missing out on a small amount. While treating breast cancer, it is perfectly possible to take timely measures to deal with bone loss in patients. Patients should take preventive measures, take calcium and vitamin D supplements at the right time, and exercise reasonably; 2. If necessary, calcitonin, active vitamin D or bisphosphonates can be used to stop bone loss. In addition, bisphosphonates can also effectively prevent bone metastasis in breast cancer patients, which can kill two birds with one stone.